Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888445 | 0.95 | TLR7 (0.42) | TLR7DYRK1ATLR8 | |
| SCHEMBL6096601 | 0.90 | TLR7 (0.48) | TLR7DYRK1AFAAHPIM1PIM3 | |
| SCHEMBL6093753 | 0.90 | FAAH (0.46) | DYRK1AFAAHPIM1PIM3DRD2 | |
| SCHEMBL1230929 | 0.89 | DYRK1A (0.43) | TLR7DYRK1AFAAHPIM1PIM3 | |
| SCHEMBL6094861 | 0.87 | TLR7 (0.47) | TLR7DYRK1ADRD2TLR8 | |
| SCHEMBL6096024 | 0.87 | DYRK1A (0.44) | DYRK1AFAAHPIM1PIM3DRD2 | |
| SCHEMBL1233520 | 0.86 | ALDH1A1 (0.38) | TLR7DYRK1ADRD2 | |
| SCHEMBL6096304 | 0.83 | BRD4 (0.38) | DYRK1AFAAHDRD2 | |
| SCHEMBL6095557 | 0.82 | DRD2 (0.40) | DYRK1AFAAHDRD2CYP3A4CYP2D6 | |
| SCHEMBL4792366 | 0.81 | HPGD (0.39) | TLR7MAPTTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050282854-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-22 | — | — | US | disclosed |
| US-6969722-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-6878719-B2 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040186128-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-6720422-B2 | MODULATORS OF IMMUNE RESPONSE BY INDUCTION OF CYTOKINE BIOSYNTHESIS; SUBSTITUTED 4-PHENOXY-IMIDAZO(4,5-C)PYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-6720333-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; N-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)BENZAMIDE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-6696465-B2 | INDUCING BIOSYNTHESIS OF CYTOKINES; VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-24 | — | — | US | disclosed |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186128-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885DYRK1A 4579/4885FAAH 2542/4885 |
| US-20050282854-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885DYRK1A 4579/4885FAAH 2542/4885 |
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | IRF3, EIF2AK2, MYD88 | TLR7 52/4885DYRK1A 3740/4885FAAH 4307/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885DYRK1A 4579/4885FAAH 2542/4885 |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | IRF3, EIF2AK2, MYD88 | TLR7 52/4885DYRK1A 3740/4885FAAH 4307/4885 |
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885DYRK1A 4579/4885FAAH 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.